



Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

January 7, 2015

GAITHERSBURG, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 11:30 a.m. PT in San Francisco, CA at The Westin St. Francis Hotel.

A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

[Novavax logo](#)

Novavax, Inc.